Marginal zone B lymphocytes and blood borne pathogens
边缘区 B 淋巴细胞和血源性病原体
基本信息
- 批准号:6721313
- 负责人:
- 金额:$ 28.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-04-01 至 2005-03-31
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyteBacillus anthracisBacillus subtilisT lymphocyteanthraxantibody specificityantigen presentationbacteria infection mechanismbacterial antigensbactericidal immunitybioterrorism /chemical warfarechimeric proteinsenzyme linked immunosorbent assaygene targetinggenetically modified animalshemotoxinhost organism interactionhumoral immunitylaboratory mouselysozymepolyglutamatespolymerase chain reactionpulmonary respirationvirulence
项目摘要
A major stage in the development of full-blown inhalation anthrax is the development of overwhelming bacteremia. A prominent cell type that provides protection against blood borne antigens is the marginal zone B cell. Attempts will be made to target the polyglutamate capsule and the protective antigen of anthrax to marginal zone B cells, in our proposed studies we will use mutant mice in an attempt to evaluate the role of MZ B cells in protective responses against blood-borne antigens. We will ask whether the polyglutamate capsule can be rendered immunogenic either by attempting to target it to MZ B cells, or by preserving it conformationally as a multivalent antigen. We will also examine whether the immune response to PA can be
enhanced by generating a PA-C3d fusion protein or by using a PA-polysaccharide conjugate in an attempt to redirect it to MZ B cells. We will then address the general issue as to whether the reason why some antigen-C3d fusions have been successful is because the antigen was targeted to MZ B cells, using lysozyme specific B cells and lysozyme-C3d fusion proteins as a model system. We will use lysozyme-specific MZ B cells to attempt to ask what is required beyond antigen per se to initiate proliferation of antigen-specific MZ B cells. Finally we will attempt to determine whether antigen-specific MZ B cells, as opposed to follicuar B cells, can readily capture and present blood borne antigens, and thus activate na'fve T cells.
一个主要阶段的发展,全面吸入炭疽是压倒性菌血症的发展。边缘区B细胞是一种主要的抗血源性抗原的细胞类型。将尝试将聚谷氨酸囊和炭疽保护性抗原靶向边缘区B细胞,在我们提出的研究中,我们将使用突变小鼠,试图评估MZ B细胞在对抗血源性抗原的保护性应答中的作用。我们将询问是否可以通过尝试将聚谷氨酸胶囊靶向MZ B细胞或通过将其构象保留为多价抗原来使其具有免疫原性。我们还将研究是否可以免疫反应PA
通过产生PA-C3 d融合蛋白或通过使用PA-多糖缀合物以试图将其重定向至MZ B细胞来增强。然后,我们将使用溶菌酶特异性B细胞和溶菌酶-C3 d融合蛋白作为模型系统,解决一些抗原-C3 d融合成功的原因是否是因为抗原靶向MZ B细胞的一般问题。我们将使用溶菌酶特异性MZ B细胞,试图了解除了抗原本身之外,还需要什么来启动抗原特异性MZ B细胞的增殖。最后,我们将试图确定抗原特异性MZ B细胞,而不是滤泡B细胞,是否可以容易地捕获和呈递血源性抗原,从而激活幼稚T细胞。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHIV Subramaniam PILLAI其他文献
SHIV Subramaniam PILLAI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHIV Subramaniam PILLAI', 18)}}的其他基金
Training Program in Immunological Tolerance and Autoimmunity
免疫耐受和自身免疫培训计划
- 批准号:
9102896 - 财政年份:2015
- 资助金额:
$ 28.96万 - 项目类别:
Training Program in Immunological Tolerance and Autoimmunity
免疫耐受和自身免疫培训计划
- 批准号:
9264976 - 财政年份:2015
- 资助金额:
$ 28.96万 - 项目类别:
Training Program in Immunological Tolerance and Autoimmunity
免疫耐受和自身免疫培训计划
- 批准号:
8933644 - 财政年份:2015
- 资助金额:
$ 28.96万 - 项目类别:
An Autoimmune center of excellence for the study of IgG4-related disease
研究 IgG4 相关疾病的自身免疫卓越中心
- 批准号:
8680709 - 财政年份:2014
- 资助金额:
$ 28.96万 - 项目类别:
Coordinating an ACE studying IgG4-related diseases
协调 ACE 研究 IgG4 相关疾病
- 批准号:
10188398 - 财政年份:2014
- 资助金额:
$ 28.96万 - 项目类别:
An autoimmune center of excellence for the study of IgG4-related disease
研究 IgG4 相关疾病的自身免疫卓越中心
- 批准号:
9915860 - 财政年份:2014
- 资助金额:
$ 28.96万 - 项目类别:
Studies on the Immunology of IgG4-related diseases
IgG4相关疾病的免疫学研究
- 批准号:
8732923 - 财政年份:2014
- 资助金额:
$ 28.96万 - 项目类别:
Coordinating an ACE studying IgG4-related diseases
协调 ACE 研究 IgG4 相关疾病
- 批准号:
10394915 - 财政年份:2014
- 资助金额:
$ 28.96万 - 项目类别:
An autoimmune center of excellence for the study of IgG4-related disease
研究 IgG4 相关疾病的自身免疫卓越中心
- 批准号:
10188397 - 财政年份:2014
- 资助金额:
$ 28.96万 - 项目类别:
相似海外基金
Development of a novel anthrax vaccine utilizing capsule biosynthesis protein CapA of Bacillus anthracis
利用炭疽杆菌荚膜生物合成蛋白CapA开发新型炭疽疫苗
- 批准号:
23K19460 - 财政年份:2023
- 资助金额:
$ 28.96万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Identification and characterization of a comprehensive set of factors required for sporulation and germination in Bacillus anthracis
炭疽芽孢杆菌孢子形成和萌发所需的一系列综合因素的鉴定和表征
- 批准号:
10510204 - 财政年份:2022
- 资助金额:
$ 28.96万 - 项目类别:
Identification and characterization of a comprehensive set of factors required for sporulation and germination in Bacillus anthracis
炭疽芽孢杆菌孢子形成和萌发所需的一系列综合因素的鉴定和表征
- 批准号:
10632069 - 财政年份:2022
- 资助金额:
$ 28.96万 - 项目类别:
Task A08: In Vitro Bacillus anthracis Lethal Toxin Neutralization Assay for Assessment of 5 Anti-Lethal Factor VHH Clones
任务 A08:用于评估 5 个抗致死因子 VHH 克隆的体外炭疽杆菌致死毒素中和测定
- 批准号:
10078441 - 财政年份:2019
- 资助金额:
$ 28.96万 - 项目类别:
Bio-imaging of the Bacillus anthracis spore coat
炭疽芽孢杆菌孢子衣的生物成像
- 批准号:
1945401 - 财政年份:2017
- 资助金额:
$ 28.96万 - 项目类别:
Studentship
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
针对炭疽杆菌的感染部位靶向抗毒素抗体 (ISTAb)
- 批准号:
10199998 - 财政年份:2017
- 资助金额:
$ 28.96万 - 项目类别:
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
针对炭疽杆菌的感染部位靶向抗毒素抗体 (ISTAb)
- 批准号:
9973142 - 财政年份:2017
- 资助金额:
$ 28.96万 - 项目类别:
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
针对炭疽杆菌的感染部位靶向抗毒素抗体 (ISTAb)
- 批准号:
10817474 - 财政年份:2017
- 资助金额:
$ 28.96万 - 项目类别:
Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis
针对炭疽杆菌的感染部位靶向抗毒素抗体 (ISTAb)
- 批准号:
9255053 - 财政年份:2017
- 资助金额:
$ 28.96万 - 项目类别:
Molecular epidemiology of Bacillus anthracis: Novel data and techniques for surveillance in endemic settings
炭疽杆菌的分子流行病学:流行环境监测的新数据和技术
- 批准号:
471750-2015 - 财政年份:2017
- 资助金额:
$ 28.96万 - 项目类别:
Postdoctoral Fellowships